These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1426 related items for PubMed ID: 16772865

  • 1. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M.
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [Abstract] [Full Text] [Related]

  • 2. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
    Green AI.
    J Clin Psychiatry; 2006 Jun; 67 Suppl 7():31-5; quiz 36-7. PubMed ID: 16961422
    [Abstract] [Full Text] [Related]

  • 3. Schizophrenia and comorbid substance use disorder: effects of antipsychotics.
    Green AI.
    J Clin Psychiatry; 2005 Jun; 66 Suppl 6():21-6. PubMed ID: 16107180
    [Abstract] [Full Text] [Related]

  • 4. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM.
    J Clin Psychiatry; 2006 Jun; 67 Suppl 5():9-14. PubMed ID: 16822091
    [Abstract] [Full Text] [Related]

  • 5. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T, Liraud F, Verdoux H.
    Encephale; 2003 Jun; 29(5):430-7. PubMed ID: 14615692
    [Abstract] [Full Text] [Related]

  • 6. Poison or cure: meanings of medication in schizophrenia.
    Rosenfield PJ.
    J Am Acad Psychoanal Dyn Psychiatry; 2007 Jun; 35(2):189-201. PubMed ID: 17650972
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
    Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA.
    J Nerv Ment Dis; 2006 Mar; 194(3):164-72. PubMed ID: 16534433
    [Abstract] [Full Text] [Related]

  • 10. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ.
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [Abstract] [Full Text] [Related]

  • 11. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C.
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [Abstract] [Full Text] [Related]

  • 12. Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients.
    Sokolski KN, Cummings JL, Abrams BI, DeMet EM, Katz LS, Costa JF.
    J Clin Psychiatry; 1994 Sep; 55(9):380-7. PubMed ID: 7929017
    [Abstract] [Full Text] [Related]

  • 13. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
    Potvin S, Stip E, Lipp O, Roy MA, Demers MF, Bouchard RH, Gendron A.
    Am J Drug Alcohol Abuse; 2008 Sep; 34(1):75-82. PubMed ID: 18161645
    [Abstract] [Full Text] [Related]

  • 14. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J, Bitter I.
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [Abstract] [Full Text] [Related]

  • 15. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
    Leucht S, Heres S.
    J Clin Psychiatry; 2006 Feb; 67 Suppl 5():3-8. PubMed ID: 16822090
    [Abstract] [Full Text] [Related]

  • 16. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.
    San L, Arranz B, Martinez-Raga J.
    Eur Addict Res; 2007 Feb; 13(4):230-43. PubMed ID: 17851245
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA, Burns T, Kemmler G, Fleischhacker WW.
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [Abstract] [Full Text] [Related]

  • 19. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A, San L, Bernardo M, Olivares JM, Polavieja P, Valladares A, Gilaberte I.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar 30; 36(2):245-50. PubMed ID: 22056291
    [Abstract] [Full Text] [Related]

  • 20. Behavioral interventions for dual-diagnosis patients.
    Goldsmith RJ, Garlapati V.
    Psychiatr Clin North Am; 2004 Dec 30; 27(4):709-25. PubMed ID: 15550289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.